Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
30 affiliations
- 1Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 2European Institute of Oncology IRCCS, Milan, Italy
- 3Sun Yat-sen University Cancer Center, Guangzhou, China
- 4British Columbia Cancer and University of British Columbia, Vancouver, BC, Canada
- 5Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Spain
- 6Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 7UC San Diego Moores Cancer Center, San Diego, CA, USA
- 8Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- 9Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
- 10Regina Elena National Cancer Institute, Rome, Italy
- 11Institut Curie, Paris, France
- 12Lung Unit, Royal Marsden Hospital, London, UK
- 13Division of Clinical Studies, Institute of Cancer Research, London, UK
- 14Hunan Cancer Hospital, Changsha, China
- 15Fujian Provincial Tumor Hospital, Fuzhou, China
- 16The Second Hospital of Anhui Medical University, Hefei, China
- 17The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 18Renmin Hospital of Wuhan University, Wuhan, China
- 19Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
- 20Service de Pneumologie, CHI Créteil, Créteil, France
- 21Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
- 22Hospital Universitario A Coruña, Health Research Institute, Coruña, Spain
- 23SCRI Oncology Partners, Rocky Mountain Cancer Centers, Lone Tree, CO, USA
- 24Valkyrie Clinical Trials, Los Angeles, CA, USA
- 25Virginia Cancer Specialists Research Institute, Fairfax, VA, USA
- 26NEXT Oncology, Fairfax, VA, USA
- 27Léon Bérard Cancer Center of Lyon, Lyon, France
- 28UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, USA
- 29Summit Therapeutics, Palo Alto, CA, USA
- 30UCLA Health, Los Angeles, CA, USA
Abstract
Plain Language Summary: What is this summary about?
HARMONi is a study of a new treatment for people with advanced or metastatic non–small cell lung cancer (NSCLC) with an activating mutation in the epidermal growth factor receptor (EGFR) gene. The study included participants in Asia, Europe, and North America whose cancer had gotten worse after treatment with an EGFR tyrosine kinase inhibitor (EGFR-TKI).
Ivonescimab is a new type of cancer treatment that helps the immune system recognize and attack tumor cells. It also blocks the formation of new blood vessels that tumors need to grow. HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy.
What were the results?
Participants who were given ivonescimab plus chemotherapy lived longer without their cancer getting worse or spreading (called progression-free survival). The median progression-free survival was 6.8 months with ivonescimab plus chemotherapy compared with 4.4 months with placebo plus chemotherapy. This difference was statistically significant. The median overall survival, or the amount of time participants lived after starting treatment, was longer with ivonescimab plus chemotherapy (median, 16.8 months) compared with placebo plus chemotherapy (median, 14.0 months); however, this difference was not statistically significant.
Two hundred and seven of 218 participants (95%, or about 9 out of every 10) who were given ivonescimab plus chemotherapy and 203 of 218 participants (93%, or about 9 out of every 10) who were given placebo plus chemotherapy had side effects related to their treatment. Common side effects with ivonescimab plus chemotherapy included changes in blood cell levels, nausea, decreased appetite, vomiting, and changes in liver enzymes. Some participants in each treatment group had severe or serious side effects. Four participants who received ivonescimab plus chemotherapy and five who received placebo plus chemotherapy died from treatment-related side effects.
What do the results mean?
For participants whose advanced NSCLC had gotten worse after EGFR-TKI treatment, ivonescimab plus chemotherapy resulted in a reduced risk of cancer getting worse or spreading by nearly half, compared with placebo plus chemotherapy. Overall survival was longer with ivonescimab plus chemotherapy; however, the difference was not statistically significant. Side effects occurred in a similar proportion of participants in both treatment groups. Most side effects could be managed without significantly impacting the participants’ quality of life or requiring treatment discontinuation.
Clinical trial number: NCT06396065
Related
- Cost-effectiveness analysis of ivonescimab plus chemotherapy in advanced squamous NSCLC: a Chinese healthcare system perspective with U.S. pricing scenario exploration
- Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial
- Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
- Cost-effectiveness of disitamab vedotin plus toripalimab versus chemotherapy alone as first-line treatment for HER2-overexpressing advanced urothelial carcinoma: a cost-effectiveness analysis from the Chinese healthcare system perspective
- Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer
BibTeX
@article{le2026plain,
title = {{Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study}},
author = {Xiuning Le and Antonio Passaro and Yuanyuan Zhao and Yan Huang and Janessa Laskin and Delvys Rodriguez-Abreu and Antonio Calles and Lyudmila Bazhenova and Giuseppe Lo Russo and Natasha B. Leighl and Federico Cappuzzo and Nicolas Girard and Sanjay Popat and Wenfeng Fang and Yongzhong Luo and Zhiyong He and Hui Zhao and Mingjun Li and Qibin Song and Hongyun Zhao and Haidar El Darsa and Isabelle Monnet and Manuel Cobo Dols and Rosario García Campelo and Robert Jotte and David Berz and Alexander Spira and Maurice Pérol and Misako Nagasaka and Howard West and Jianling Li and Fong Clow and Amy C. Moore and Jonathan Goldman and Zhang Li},
journal = {Future Oncology},
year = {2026},
month = nov,
doi = {10.1080/14796694.2026.2749355},
url = {https://doi.org/10.1080/14796694.2026.2749355},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
AU - Xiuning Le
AU - Antonio Passaro
AU - Yuanyuan Zhao
AU - Yan Huang
AU - Janessa Laskin
AU - Delvys Rodriguez-Abreu
AU - Antonio Calles
AU - Lyudmila Bazhenova
AU - Giuseppe Lo Russo
AU - Natasha B. Leighl
AU - Federico Cappuzzo
AU - Nicolas Girard
AU - Sanjay Popat
AU - Wenfeng Fang
AU - Yongzhong Luo
AU - Zhiyong He
AU - Hui Zhao
AU - Mingjun Li
AU - Qibin Song
AU - Hongyun Zhao
AU - Haidar El Darsa
AU - Isabelle Monnet
AU - Manuel Cobo Dols
AU - Rosario García Campelo
AU - Robert Jotte
AU - David Berz
AU - Alexander Spira
AU - Maurice Pérol
AU - Misako Nagasaka
AU - Howard West
AU - Jianling Li
AU - Fong Clow
AU - Amy C. Moore
AU - Jonathan Goldman
AU - Zhang Li
PY - 2026
DA - 2026/11/04
JO - Future Oncology
DO - 10.1080/14796694.2026.2749355
UR - https://doi.org/10.1080/14796694.2026.2749355
AB - Plain Language Summary: What is this summary about? HARMONi is a study of a new treatment for people with advanced or metastatic non–small cell lung cancer (NSCLC) with an activating mutation in the epidermal growth factor receptor (EGFR) gene. The study included participants in Asia, Europe, and North America whose cancer had gotten worse after treatment with an EGFR tyrosine kinase inhibitor (EGFR-TKI). Ivonescimab is a new type of cancer treatment that helps the immune system recognize and attack tumor cells. It also blocks the formation of new blood vessels that tumors need to grow. HARMONi compared ivonescimab plus chemotherapy with placebo plus chemotherapy. What were the results? Participants who were given ivonescimab plus chemotherapy lived longer without their cancer getting worse or spreading (called progression-free survival). The median progression-free survival was 6.8 months with ivonescimab plus chemotherapy compared with 4.4 months with placebo plus chemotherapy. This difference was statistically significant. The median overall survival, or the amount of time participants lived after starting treatment, was longer with ivonescimab plus chemotherapy (median, 16.8 months) compared with placebo plus chemotherapy (median, 14.0 months); however, this difference was not statistically significant. Two hundred and seven of 218 participants (95%, or about 9 out of every 10) who were given ivonescimab plus chemotherapy and 203 of 218 participants (93%, or about 9 out of every 10) who were given placebo plus chemotherapy had side effects related to their treatment. Common side effects with ivonescimab plus chemotherapy included changes in blood cell levels, nausea, decreased appetite, vomiting, and changes in liver enzymes. Some participants in each treatment group had severe or serious side effects. Four participants who received ivonescimab plus chemotherapy and five who received placebo plus chemotherapy died from treatment-related side effects. What do the results mean? For participants whose advanced NSCLC had gotten worse after EGFR-TKI treatment, ivonescimab plus chemotherapy resulted in a reduced risk of cancer getting worse or spreading by nearly half, compared with placebo plus chemotherapy. Overall survival was longer with ivonescimab plus chemotherapy; however, the difference was not statistically significant. Side effects occurred in a similar proportion of participants in both treatment groups. Most side effects could be managed without significantly impacting the participants’ quality of life or requiring treatment discontinuation. Clinical trial number: NCT06396065
SN - 1479-6694
SN - 1744-8301
ER -